Skip to main content

Table 4 Satisfaction regarding IgRT at enrollment

From: Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

  LQI Factor I LQI Factor II LQI Factor III
Hospital-based IVIg 81.2 ± 2.5 85.8 ± 2.3 82.3 ± 2.5
Home-based IVIg 72.8 ± 4.7 79.5 ± 4.1 86.9 ± 4.5
Home-based SCIg 85.6 ± 2.3 85.6 ± 1.9 91.5 ± 2.2
Hospital-based IVIg vs home based IVIg [-2.3 to 19.0]
P = 0.12
[-2.8 to 15.5]
P = 0.17
[14.8 to 5.5
P = 0.37
Hospital-based IVIg vs home based SCIg [-11.1 to 2.2]
P = 0.19
[-5.5 to 6.0]
P = 0.93
[-15.5 to -2.8]
P = 0.005
Home-based IVIg vs home based SCIg [-23.3 to -2.3]
P = 0.02
[-15.1 to 2.9]
P = 0.18
[-14.6 to 5.4]
P = 0.37
  1. Results are expressed as mean ± standard error. Contrasts are derived from a mixed model with route, place and route by place interaction as fixed factor and center as random factor. Contrasts are provided as two-sided 95 % confidence interval and p value